Image
Comprehensive Management of Chronic Obstructive Pulmonary Disease Collaborative Approaches to Guideline-Concordant Patient Care

James F. Donohue, MD; Fernando J. Martinez, MD, MS; Barbara P. Yawn, MD, MSc, FAAFP

 

This activity is jointly provided by Global Education Group and Integritas Communications.

This activity is supported by an educational grant from AstraZeneca. 

 

Faculty

James F. Donohue,MD
Professor of Medicine
Division of Pulmonary Diseases and Critical Care Medicine
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Fernando J. Martinez, MD, MS
Executive Vice Chair of Medicine
Gladys and Roland Harriman Professor of Medicine
Joan and Sanford I. Weil Department of Medicine
Weil Cornell Medical College
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York

Barbara P. Yawn, MD, MSc, FAAFP
Adjunct Professor in Family and Community Health
University of Minnesota
Director of Research
Olmsted Medical Center
Rochester, Minnesota

Target Audience

The educational design of this activity addresses the needs of primary care providers and other clinicians involved in the identification and ongoing management of patients with chronic obstructive pulmonary disease (COPD).

Statement of Need/Program Overview

Identification and management of patients with chronic obstructive pulmonary disease (COPD) can be difficult in a primary care setting. Frequent updates to practice recommendations from COPD management guidelines and advances in treatment options place additional challenges on clinicians to stay abreast of the latest developments in the field. This Clinical Research Updates roundtable reviews practical strategies to identify and longitudinally monitor patients with chronic airway limitation. The expert faculty panel examines best practices for selecting appropriate maintenance therapy, including escalation of therapy for patients with frequent exacerbations, as well as referral of certain patients to specialty care. Inclusion of a patient interview highlights the need for prompt diagnosis, benefits of nonpharmacologic treatment, including pulmonary rehabilitation, and the importance of patient education for patients with COPD.

Educational Objectives

After completing this activity, the participant will be better able to: 

  • Comprehensively assess individuals who are at-risk for COPD for relevant symptoms, spirometry results, physical activity levels, and other relevant clinical parameters
  • Prescribe multimodal maintenance therapy for patients with COPD based on disease severity, clinical profiles of available medications, and patient preferences
  • Tailor maintenance regimens to reflect current patient status, treatment responses, and exacerbation risks
  • Engage patients with COPD and their caregivers in shared decision-making to encourage self-management and treatment adherence

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity..

Nurse Practitioner Continuing Education

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standard.Global Education Group is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 110121. This program has been approved for 1.0 contact hour of continuing education (which includes 0.2 hour of pharmacology).

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or
inquire@globaleducationgroup.com

Instructions to Receive Credit

In order to receive credit for this activity, the attendee must achieve a score of 70% or higher on the posttest and complete the program evaluation.

System Requirements

PC
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v7.0.1.9 or greater)
Adobe Acrobat Reader

MAC
MAC OS 10.2.8
Flash Player Plugin (v7.0.1.9 or greater)
Safari
Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity: 

James F. Donohue,MD     Consultant: AstraZeneca plc, Boehringer Ingelheim GmbH, GlaxoSmithKline, Mylan N.V., Novartis Pharmaceuticals, and Sunovion Pharmaceuticals Inc. Honoraria from AstraZeneca plc, Gilead Sciences, Inc., (CSA ), Insmed Inc., Novartis Pharmaceuticals, PneumRx, and Teva Pharmaceuticals Industries Ltd.

Fernando J. Martinez, MD, MS     Consultant/Independent Contractor to AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, Genentech Inc., GlaxoSmithKline plc, Ikaria, Inc/Bellerophon Therapeutics, Kadmon Corporation, LLC, Novartis Pharmaceuticals, Pearl Therapeutics, Skyepharma PLC, and Veracyte, Inc. Grant/Research Support from Afferent Pharmaceuticals, Inc., Bayer AG, Boehringer Ingelheim GmbH, Forest Laboratories, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, and Takeda Pharmaceuticals USA, Inc. Honoraria from Biogen and GlaxoSmithKline plc (DSMBs). Speakers Bureau to AstraZeneca plc and Takeda Pharmaceuticals USA, Inc. (European Respiratory Society)

Barbara P. Yawn, MD, MSc, FAAFP     Consultant/Independent Contractor AstraZeneca plc, Boehringer Ingelheim GmbH, and Novartis Pharmaceuticals. Grant/Research Support from Boehringer Ingelheim GmbH.

The following planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Amanda Glazar, PhD      Nothing to disclose
Andrea Funk      Nothing to disclose
Laura Gilsdorf      Nothing to disclose
Jim Kappler, PhD      Nothing to disclose
Kristen Delisi, NP      Nothing to disclose

 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

expiration 08/30/2017

type Webcast